
Non-alcoholic Steatohepatitis Treatment Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type
Description
Non-alcoholic Steatohepatitis Treatment Market Summary
and Market Overview
Non-alcoholic steatohepatitis (NASH) treatments, including vitamin E, obeticholic acid, and resmetirom, address a progressive liver disease driven by obesity (650 million adults globally), type 2 diabetes (537 million cases), and metabolic syndrome. NASH, projected to affect 27 million U.S. patients by 2030, is a leading cause of liver transplants and increases cardiovascular risk by 50%. The market is propelled by rising prevalence, non-invasive diagnostics improving accuracy by 40%, and accelerated regulatory approvals, such as Rezdiffra in 2024. Government funding, including USD 2.31 billion from NIDDK, and 60% OECD reimbursement coverage further drive growth. The global NASH treatment market is estimated at USD 5.0-9.0 billion in 2025, with a CAGR of 22%-30% through 2030.
Regional Market Trends
North America: The U.S. leads with high obesity rates and Rezdiffra adoption, while Canada emphasizes metabolic health programs.
Europe: Germany, France, and the UK drive growth with advanced liver disease management and biomarker adoption.
Asia Pacific: China and India see rising NASH cases due to lifestyle changes, with Japan focusing on novel therapies.
Rest of the World: Brazil expands diagnostic infrastructure, while the Middle East addresses diabetes-related NASH.
Distribution Channel Analysis
Hospital Pharmacies: Expected growth of 22.5%-30.5%, driven by novel therapies like resmetirom. Trends focus on specialized liver care.
Retail and Specialty Pharmacies: Projected growth of 22.0%-30.0%, linked to outpatient management. Advances emphasize patient access.
Other Pharmacies: Anticipated growth of 21.5%-29.5%, covering online platforms. Trends highlight digital prescriptions.
Type Analysis
Vitamin E and Pioglitazone: Expected growth of 20.0%-28.0%, used for early-stage NASH. Trends focus on cost-effective options for mild cases.
Obeticholic Acid (OCA): Projected growth of 22.5%-30.5%, effective for fibrosis. Advances emphasize regulatory progress and combination therapies.
Lanifibranor: Anticipated growth of 23.0%-31.0%, valued for multi-pathway action. Trends highlight metabolic and anti-fibrotic benefits.
Semaglutide: Expected growth of 22.8%-30.8%, leveraging weight loss and diabetes synergy. Developments prioritize dual indications.
Resmetirom: Expected growth of 24.0%-32.0%, a first-in-class therapy reducing liver fat. Trends focus on transformative outcomes.
Aramchol: Expected growth of 21.5%-29.5%, targeting steatosis. Trends highlight potential in combination regimens.
Cenicriviroc: Expected growth of 21.0%-29.0%, addressing inflammation. Developments prioritize anti-fibrotic effects.
Other Drugs: Expected growth of 20.5%-28.5%, covering pipeline candidates. Trends focus on diverse mechanisms.
Key Market Players
Madrigal Pharmaceuticals: Pioneers resmetirom for NASH treatment.
Intercept Pharmaceuticals: Develops obeticholic acid for fibrosis.
Inventiva: Focuses on lanifibranor for metabolic benefits.
Novo Nordisk: Offers semaglutide, leveraging diabetes expertise.
Pfizer: Innovates combination therapies for NASH.
Porter’s Five Forces Analysis
Threat of New Entrants: Moderate, as high R&D costs and regulatory hurdles exist, but unmet medical needs attract new players.
Threat of Substitutes: Moderate, with lifestyle interventions competing, but advanced NASH requires pharmacological solutions.
Bargaining Power of Buyers: Moderate, as insurers negotiate prices, but limited approved therapies strengthen providers.
Bargaining Power of Suppliers: Low, with multiple suppliers of active pharmaceutical ingredients.
Competitive Rivalry: High, with companies competing on efficacy, safety, and speed to market.
Market Opportunities and Challenges
Opportunities:
Addressing NASH, projected to affect 27 million U.S. patients by 2030.
Leveraging obesity and diabetes, impacting 650 million and 537 million people, respectively.
Utilizing non-invasive diagnostics, improving accuracy by 40%.
Benefiting from USD 2.31 billion NIDDK funding for research.
Expanding 60% OECD reimbursement coverage for NASH therapies.
Developing combination therapies for comprehensive management.
Challenges:
High costs of novel therapies limiting patient access.
Regulatory delays for pipeline drugs.
Limited NASH awareness and diagnostics in developing regions.
Competition from lifestyle-based interventions.
Complexity in managing advanced NASH and comorbidities.
and Market Overview
Non-alcoholic steatohepatitis (NASH) treatments, including vitamin E, obeticholic acid, and resmetirom, address a progressive liver disease driven by obesity (650 million adults globally), type 2 diabetes (537 million cases), and metabolic syndrome. NASH, projected to affect 27 million U.S. patients by 2030, is a leading cause of liver transplants and increases cardiovascular risk by 50%. The market is propelled by rising prevalence, non-invasive diagnostics improving accuracy by 40%, and accelerated regulatory approvals, such as Rezdiffra in 2024. Government funding, including USD 2.31 billion from NIDDK, and 60% OECD reimbursement coverage further drive growth. The global NASH treatment market is estimated at USD 5.0-9.0 billion in 2025, with a CAGR of 22%-30% through 2030.
Regional Market Trends
North America: The U.S. leads with high obesity rates and Rezdiffra adoption, while Canada emphasizes metabolic health programs.
Europe: Germany, France, and the UK drive growth with advanced liver disease management and biomarker adoption.
Asia Pacific: China and India see rising NASH cases due to lifestyle changes, with Japan focusing on novel therapies.
Rest of the World: Brazil expands diagnostic infrastructure, while the Middle East addresses diabetes-related NASH.
Distribution Channel Analysis
Hospital Pharmacies: Expected growth of 22.5%-30.5%, driven by novel therapies like resmetirom. Trends focus on specialized liver care.
Retail and Specialty Pharmacies: Projected growth of 22.0%-30.0%, linked to outpatient management. Advances emphasize patient access.
Other Pharmacies: Anticipated growth of 21.5%-29.5%, covering online platforms. Trends highlight digital prescriptions.
Type Analysis
Vitamin E and Pioglitazone: Expected growth of 20.0%-28.0%, used for early-stage NASH. Trends focus on cost-effective options for mild cases.
Obeticholic Acid (OCA): Projected growth of 22.5%-30.5%, effective for fibrosis. Advances emphasize regulatory progress and combination therapies.
Lanifibranor: Anticipated growth of 23.0%-31.0%, valued for multi-pathway action. Trends highlight metabolic and anti-fibrotic benefits.
Semaglutide: Expected growth of 22.8%-30.8%, leveraging weight loss and diabetes synergy. Developments prioritize dual indications.
Resmetirom: Expected growth of 24.0%-32.0%, a first-in-class therapy reducing liver fat. Trends focus on transformative outcomes.
Aramchol: Expected growth of 21.5%-29.5%, targeting steatosis. Trends highlight potential in combination regimens.
Cenicriviroc: Expected growth of 21.0%-29.0%, addressing inflammation. Developments prioritize anti-fibrotic effects.
Other Drugs: Expected growth of 20.5%-28.5%, covering pipeline candidates. Trends focus on diverse mechanisms.
Key Market Players
Madrigal Pharmaceuticals: Pioneers resmetirom for NASH treatment.
Intercept Pharmaceuticals: Develops obeticholic acid for fibrosis.
Inventiva: Focuses on lanifibranor for metabolic benefits.
Novo Nordisk: Offers semaglutide, leveraging diabetes expertise.
Pfizer: Innovates combination therapies for NASH.
Porter’s Five Forces Analysis
Threat of New Entrants: Moderate, as high R&D costs and regulatory hurdles exist, but unmet medical needs attract new players.
Threat of Substitutes: Moderate, with lifestyle interventions competing, but advanced NASH requires pharmacological solutions.
Bargaining Power of Buyers: Moderate, as insurers negotiate prices, but limited approved therapies strengthen providers.
Bargaining Power of Suppliers: Low, with multiple suppliers of active pharmaceutical ingredients.
Competitive Rivalry: High, with companies competing on efficacy, safety, and speed to market.
Market Opportunities and Challenges
Opportunities:
Addressing NASH, projected to affect 27 million U.S. patients by 2030.
Leveraging obesity and diabetes, impacting 650 million and 537 million people, respectively.
Utilizing non-invasive diagnostics, improving accuracy by 40%.
Benefiting from USD 2.31 billion NIDDK funding for research.
Expanding 60% OECD reimbursement coverage for NASH therapies.
Developing combination therapies for comprehensive management.
Challenges:
High costs of novel therapies limiting patient access.
Regulatory delays for pipeline drugs.
Limited NASH awareness and diagnostics in developing regions.
Competition from lifestyle-based interventions.
Complexity in managing advanced NASH and comorbidities.
Table of Contents
80 Pages
- Chapter 1 Executive Summary
- Chapter 2 Abbreviation and Acronyms
- Chapter 3 Preface
- 3.1 Research Scope
- 3.2 Research Sources
- 3.2.1 Data Sources
- 3.2.2 Assumptions
- 3.3 Research Method
- Chapter Four Market Landscape
- 4.1 Market Overview
- 4.2 Classification/Types
- 4.3 Application/End Users
- Chapter 5 Market Trend Analysis
- 5.1 Introduction
- 5.2 Drivers
- 5.3 Restraints
- 5.4 Opportunities
- 5.5 Threats
- Chapter 6 Industry Chain Analysis
- 6.1 Upstream/Suppliers Analysis
- 6.2 Non-Alcoholic Steatohepatitis Treatment Analysis
- 6.2.1 Technology Analysis
- 6.2.2 Cost Analysis
- 6.2.3 Market Channel Analysis
- 6.3 Downstream Buyers/End Users
- Chapter 7 Latest Market Dynamics
- 7.1 Latest News
- 7.2 Merger and Acquisition
- 7.3 Planned/Future Project
- 7.4 Policy Dynamics
- Chapter 8 Historical and Forecast Non-Alcoholic Steatohepatitis Treatment Market in North America (2020-2030)
- 8.1 Non-Alcoholic Steatohepatitis Treatment Market Size
- 8.2 Non-Alcoholic Steatohepatitis Treatment Market by End Use
- 8.3 Competition by Players/Suppliers
- 8.4 Non-Alcoholic Steatohepatitis Treatment Market Size by Type
- 8.5 Key Countries Analysis
- 8.5.1 United States
- 8.5.2 Canada
- 8.5.3 Mexico
- Chapter 9 Historical and Forecast Non-Alcoholic Steatohepatitis Treatment Market in South America (2020-2030)
- 9.1 Non-Alcoholic Steatohepatitis Treatment Market Size
- 9.2 Non-Alcoholic Steatohepatitis Treatment Market by End Use
- 9.3 Competition by Players/Suppliers
- 9.4 Non-Alcoholic Steatohepatitis Treatment Market Size by Type
- 9.5 Key Countries Analysis
- 9.5.1 Brazil
- 9.5.2 Argentina
- 9.5.3 Chile
- 9.5.4 Peru
- Chapter 10 Historical and Forecast Non-Alcoholic Steatohepatitis Treatment Market in Asia & Pacific (2020-2030)
- 10.1 Non-Alcoholic Steatohepatitis Treatment Market Size
- 10.2 Non-Alcoholic Steatohepatitis Treatment Market by End Use
- 10.3 Competition by Players/Suppliers
- 10.4 Non-Alcoholic Steatohepatitis Treatment Market Size by Type
- 10.5 Key Countries Analysis
- 10.5.1 China
- 10.5.2 India
- 10.5.3 Japan
- 10.5.4 South Korea
- 10.5.5 Southest Asia
- 10.5.6 Australia
- Chapter 11 Historical and Forecast Non-Alcoholic Steatohepatitis Treatment Market in Europe (2020-2030)
- 11.1 Non-Alcoholic Steatohepatitis Treatment Market Size
- 11.2 Non-Alcoholic Steatohepatitis Treatment Market by End Use
- 11.3 Competition by Players/Suppliers
- 11.4 Non-Alcoholic Steatohepatitis Treatment Market Size by Type
- 11.5 Key Countries Analysis
- 11.5.1 Germany
- 11.5.2 France
- 11.5.3 United Kingdom
- 11.5.4 Italy
- 11.5.5 Spain
- 11.5.6 Belgium
- 11.5.7 Netherlands
- 11.5.8 Austria
- 11.5.9 Poland
- 11.5.10 Russia
- Chapter 12 Historical and Forecast Non-Alcoholic Steatohepatitis Treatment Market in MEA (2020-2030)
- 12.1 Non-Alcoholic Steatohepatitis Treatment Market Size
- 12.2 Non-Alcoholic Steatohepatitis Treatment Market by End Use
- 12.3 Competition by Players/Suppliers
- 12.4 Non-Alcoholic Steatohepatitis Treatment Market Size by Type
- 12.5 Key Countries Analysis
- 12.5.1 Egypt
- 12.5.2 Israel
- 12.5.3 South Africa
- 12.5.4 Gulf Cooperation Council Countries
- 12.5.5 Turkey
- Chapter 13 Summary For Global Non-Alcoholic Steatohepatitis Treatment Market (2020-2025)
- 13.1 Non-Alcoholic Steatohepatitis Treatment Market Size
- 13.2 Non-Alcoholic Steatohepatitis Treatment Market by End Use
- 13.3 Competition by Players/Suppliers
- 13.4 Non-Alcoholic Steatohepatitis Treatment Market Size by Type
- Chapter 14 Global Non-Alcoholic Steatohepatitis Treatment Market Forecast (2025-2030)
- 14.1 Non-Alcoholic Steatohepatitis Treatment Market Size Forecast
- 14.2 Non-Alcoholic Steatohepatitis Treatment Application Forecast
- 14.3 Competition by Players/Suppliers
- 14.4 Non-Alcoholic Steatohepatitis Treatment Type Forecast
- Chapter 15 Analysis of Global Key Vendors
- 15.1 Madrigal Pharmaceuticals
- 15.1.1 Company Profile
- 15.1.2 Main Business and Non-alcoholic Steatohepatitis Treatment Information
- 15.1.3 SWOT Analysis of Madrigal Pharmaceuticals
- 15.1.4 Madrigal Pharmaceuticals Non-alcoholic Steatohepatitis Treatment Revenue, Gross Margin and Market Share (2020-2025)
- 15.2 Intercept Pharmaceuticals
- 15.2.1 Company Profile
- 15.2.2 Main Business and Non-alcoholic Steatohepatitis Treatment Information
- 15.2.3 SWOT Analysis of Intercept Pharmaceuticals
- 15.2.4 Intercept Pharmaceuticals Non-alcoholic Steatohepatitis Treatment Revenue, Gross Margin and Market Share (2020-2025)
- 15.3 Inventiva
- 15.3.1 Company Profile
- 15.3.2 Main Business and Non-alcoholic Steatohepatitis Treatment Information
- 15.3.3 SWOT Analysis of Inventiva
- 15.3.4 Inventiva Non-alcoholic Steatohepatitis Treatment Revenue, Gross Margin and Market Share (2020-2025)
- 15.4 Nordisk
- 15.4.1 Company Profile
- 15.4.2 Main Business and Non-alcoholic Steatohepatitis Treatment Information
- 15.4.3 SWOT Analysis of Nordisk
- 15.4.4 Nordisk Non-alcoholic Steatohepatitis Treatment Revenue, Gross Margin and Market Share (2020-2025)
- Please ask for sample pages for full companies list
- Tables and Figures
- Table Abbreviation and Acronyms
- Table Research Scope of Non-Alcoholic Steatohepatitis Treatment Report
- Table Data Sources of Non-Alcoholic Steatohepatitis Treatment Report
- Table Major Assumptions of Non-Alcoholic Steatohepatitis Treatment Report
- Figure Market Size Estimated Method
- Figure Major Forecasting Factors
- Figure Non-Alcoholic Steatohepatitis Treatment Picture
- Table Non-Alcoholic Steatohepatitis Treatment Classification
- Table Non-Alcoholic Steatohepatitis Treatment Applications
- Table Drivers of Non-Alcoholic Steatohepatitis Treatment Market
- Table Restraints of Non-Alcoholic Steatohepatitis Treatment Market
- Table Opportunities of Non-Alcoholic Steatohepatitis Treatment Market
- Table Threats of Non-Alcoholic Steatohepatitis Treatment Market
- Table Covid-19 Impact For Non-Alcoholic Steatohepatitis Treatment Market
- Table Raw Materials Suppliers
- Table Different Production Methods of Non-Alcoholic Steatohepatitis Treatment
- Table Cost Structure Analysis of Non-Alcoholic Steatohepatitis Treatment
- Table Key End Users
- Table Latest News of Non-Alcoholic Steatohepatitis Treatment Market
- Table Merger and Acquisition
- Table Planned/Future Project of Non-Alcoholic Steatohepatitis Treatment Market
- Table Policy of Non-Alcoholic Steatohepatitis Treatment Market
- Table 2020-2030 North America Non-Alcoholic Steatohepatitis Treatment Market Size
- Figure 2020-2030 North America Non-Alcoholic Steatohepatitis Treatment Market Size and CAGR
- Table 2020-2030 North America Non-Alcoholic Steatohepatitis Treatment Market Size by Application
- Table 2020-2025 North America Non-Alcoholic Steatohepatitis Treatment Key Players Revenue
- Table 2020-2025 North America Non-Alcoholic Steatohepatitis Treatment Key Players Market Share
- Table 2020-2030 North America Non-Alcoholic Steatohepatitis Treatment Market Size by Type
- Table 2020-2030 United States Non-Alcoholic Steatohepatitis Treatment Market Size
- Table 2020-2030 Canada Non-Alcoholic Steatohepatitis Treatment Market Size
- Table 2020-2030 Mexico Non-Alcoholic Steatohepatitis Treatment Market Size
- Table 2020-2030 South America Non-Alcoholic Steatohepatitis Treatment Market Size
- Figure 2020-2030 South America Non-Alcoholic Steatohepatitis Treatment Market Size and CAGR
- Table 2020-2030 South America Non-Alcoholic Steatohepatitis Treatment Market Size by Application
- Table 2020-2025 South America Non-Alcoholic Steatohepatitis Treatment Key Players Revenue
- Table 2020-2025 South America Non-Alcoholic Steatohepatitis Treatment Key Players Market Share
- Table 2020-2030 South America Non-Alcoholic Steatohepatitis Treatment Market Size by Type
- Table 2020-2030 Brazil Non-Alcoholic Steatohepatitis Treatment Market Size
- Table 2020-2030 Argentina Non-Alcoholic Steatohepatitis Treatment Market Size
- Table 2020-2030 Chile Non-Alcoholic Steatohepatitis Treatment Market Size
- Table 2020-2030 Peru Non-Alcoholic Steatohepatitis Treatment Market Size
- Table 2020-2030 Asia & Pacific Non-Alcoholic Steatohepatitis Treatment Market Size
- Figure 2020-2030 Asia & Pacific Non-Alcoholic Steatohepatitis Treatment Market Size and CAGR
- Table 2020-2030 Asia & Pacific Non-Alcoholic Steatohepatitis Treatment Market Size by Application
- Table 2020-2025 Asia & Pacific Non-Alcoholic Steatohepatitis Treatment Key Players Revenue
- Table 2020-2025 Asia & Pacific Non-Alcoholic Steatohepatitis Treatment Key Players Market Share
- Table 2020-2030 Asia & Pacific Non-Alcoholic Steatohepatitis Treatment Market Size by Type
- Table 2020-2030 China Non-Alcoholic Steatohepatitis Treatment Market Size
- Table 2020-2030 India Non-Alcoholic Steatohepatitis Treatment Market Size
- Table 2020-2030 Japan Non-Alcoholic Steatohepatitis Treatment Market Size
- Table 2020-2030 South Korea Non-Alcoholic Steatohepatitis Treatment Market Size
- Table 2020-2030 Southeast Asia Non-Alcoholic Steatohepatitis Treatment Market Size
- Table 2020-2030 Australia Non-Alcoholic Steatohepatitis Treatment Market Size
- Table 2020-2030 Europe Non-Alcoholic Steatohepatitis Treatment Market Size
- Figure 2020-2030 Europe Non-Alcoholic Steatohepatitis Treatment Market Size and CAGR
- Table 2020-2030 Europe Non-Alcoholic Steatohepatitis Treatment Market Size by Application
- Table 2020-2025 Europe Non-Alcoholic Steatohepatitis Treatment Key Players Revenue
- Table 2020-2025 Europe Non-Alcoholic Steatohepatitis Treatment Key Players Market Share
- Table 2020-2030 Europe Non-Alcoholic Steatohepatitis Treatment Market Size by Type
- Table 2020-2030 Germany Non-Alcoholic Steatohepatitis Treatment Market Size
- Table 2020-2030 France Non-Alcoholic Steatohepatitis Treatment Market Size
- Table 2020-2030 United Kingdom Non-Alcoholic Steatohepatitis Treatment Market Size
- Table 2020-2030 Italy Non-Alcoholic Steatohepatitis Treatment Market Size
- Table 2020-2030 Spain Non-Alcoholic Steatohepatitis Treatment Market Size
- Table 2020-2030 Belgium Non-Alcoholic Steatohepatitis Treatment Market Size
- Table 2020-2030 Netherlands Non-Alcoholic Steatohepatitis Treatment Market Size
- Table 2020-2030 Austria Non-Alcoholic Steatohepatitis Treatment Market Size
- Table 2020-2030 Poland Non-Alcoholic Steatohepatitis Treatment Market Size
- Table 2020-2030 Russia Non-Alcoholic Steatohepatitis Treatment Market Size
- Table 2020-2030 MEA Non-Alcoholic Steatohepatitis Treatment Market Size
- Figure 2020-2030 MEA Non-Alcoholic Steatohepatitis Treatment Market Size and CAGR
- Table 2020-2030 MEA Non-Alcoholic Steatohepatitis Treatment Market Size by Application
- Table 2020-2025 MEA Non-Alcoholic Steatohepatitis Treatment Key Players Revenue
- Table 2020-2025 MEA Non-Alcoholic Steatohepatitis Treatment Key Players Market Share
- Table 2020-2030 MEA Non-Alcoholic Steatohepatitis Treatment Market Size by Type
- Table 2020-2030 Egypt Non-Alcoholic Steatohepatitis Treatment Market Size
- Table 2020-2030 Israel Non-Alcoholic Steatohepatitis Treatment Market Size
- Table 2020-2030 South Africa Non-Alcoholic Steatohepatitis Treatment Market Size
- Table 2020-2030 Gulf Cooperation Council Countries Non-Alcoholic Steatohepatitis Treatment Market Size
- Table 2020-2030 Turkey Non-Alcoholic Steatohepatitis Treatment Market Size
- Table 2020-2025 Global Non-Alcoholic Steatohepatitis Treatment Market Size by Region
- Table 2020-2025 Global Non-Alcoholic Steatohepatitis Treatment Market Size Share by Region
- Table 2020-2025 Global Non-Alcoholic Steatohepatitis Treatment Market Size by Application
- Table 2020-2025 Global Non-Alcoholic Steatohepatitis Treatment Market Share by Application
- Table 2020-2025 Global Non-Alcoholic Steatohepatitis Treatment Key Vendors Revenue
- Figure 2020-2025 Global Non-Alcoholic Steatohepatitis Treatment Market Size and Growth Rate
- Table 2020-2025 Global Non-Alcoholic Steatohepatitis Treatment Key Vendors Market Share
- Table 2020-2025 Global Non-Alcoholic Steatohepatitis Treatment Market Size by Type
- Table 2020-2025 Global Non-Alcoholic Steatohepatitis Treatment Market Share by Type
- Table 2025-2030 Global Non-Alcoholic Steatohepatitis Treatment Market Size by Region
- Table 2025-2030 Global Non-Alcoholic Steatohepatitis Treatment Market Size Share by Region
- Table 2025-2030 Global Non-Alcoholic Steatohepatitis Treatment Market Size by Application
- Table 2025-2030 Global Non-Alcoholic Steatohepatitis Treatment Market Share by Application
- Table 2025-2030 Global Non-Alcoholic Steatohepatitis Treatment Key Vendors Revenue
- Figure 2025-2030 Global Non-Alcoholic Steatohepatitis Treatment Market Size and Growth Rate
- Table 2025-2030 Global Non-Alcoholic Steatohepatitis Treatment Key Vendors Market Share
- Table 2025-2030 Global Non-Alcoholic Steatohepatitis Treatment Market Size by Type
- Table 2025-2030 Non-Alcoholic Steatohepatitis Treatment Global Market Share by Type
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.